Dr Patel on Findings From the TRUST-II Trial in ROS1+ NSCLC
Jyoti Patel, MD, discusses the implications of the TRUST-II trial in locally advanced or metastatic ROS1-positive NSCLC, regardless of prior TKI exposure.
Jyoti Patel, MD, discusses the implications of the TRUST-II trial in locally advanced or metastatic ROS1-positive NSCLC, regardless of prior TKI exposure.
The FDA has granted rare pediatric disease designation to galinpepimut-S for acute myeloid leukemia.
A next generation sequencing–based companion diagnostic has received marketing approval in China for sunvozertinib in EGFR exon 20–positive NSCLC.
Nancy U. Lin, MD, discusses findings from the DESTINY-Breast12 trial of trastuzumab deruxtecan in advanced HER2-positive breast cancer with brain metastases.
The burden of liver cancer varies across the world. Liver cancer was among the top three causes of cancer death in 46 countries and was…
Patients, pathologists, clinicians, researchers, radiologists and others from around the world recently gathered for the 2024 International Invasive Lobular Carcinoma Symposium, in Leuven, Belgium.
Yoshiaki Nakamura, MD, PhD, discusses how the COSMOS-CRC-01 study assessed the sensitivity and specificity of a cell-free DNA epigenomic assay in R0 stage II to…
Screening for donor-derived clonal hematopoiesis may have prognostic value for outcomes following auto-HSCT in patients with hematologic malignancies.
Retreatment with venetoclax plus rituximab generated responses in patients with CLL who had responded to and progressed after initial venetoclax treatment.
In the first part of this roundtable series moderated by Tanya Dorff, MD, the panelists discuss the use of PSMA PET scans and androgen deprivation…
The Frontiers in Cancer Science 2024 conference in Singapore includes a thematic focus on immuno-oncology, genomics, metabolism, and AI.